Clozapine and risperidone: Refining and extending their use

Peter F Buckley, S. Charles Schulz

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The recent advent of atypical antipsychotic medications has provided new clinical options and set higher expectations for the treatment of schizophrenia and other psychoses. Two such drugs, clozapine and risperidone, are currently employed in the United States. Researchers continue to fine-tune treatment with these agents and to seek possible new uses for them. For clozapine, refinements in use (optimal duration of trial, optimal dose, use of drug plasma level to optimize efficacy) are described, along with side effects and the specificity (or lack thereof) of the drug's action upon primary negative symptoms. Also discussed is use of clozapine in new subgroups of patients for example, those with first-episode schizophrenia, polydipsia syndrome, or a dual diagnosis. For risperidone, use in patients with first-episode schizophrenia, affective disorders, autism, and other disorders is described. Cost-benefit considerations are presented for both drugs. The psychosocial needs of patients taking these medications and the potential for synergy between novel antipsychotics and modern psychosocial therapies are also discussed.

Original languageEnglish (US)
Pages (from-to)184-199
Number of pages16
JournalHarvard Review of Psychiatry
Volume4
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Risperidone
Clozapine
Schizophrenia
Pharmaceutical Preparations
Antipsychotic Agents
Dual (Psychiatry) Diagnosis
Polydipsia
Autistic Disorder
Mood Disorders
Psychotic Disorders
Cost-Benefit Analysis
Therapeutics
Research Personnel

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Clozapine and risperidone : Refining and extending their use. / Buckley, Peter F; Charles Schulz, S.

In: Harvard Review of Psychiatry, Vol. 4, No. 4, 01.01.1996, p. 184-199.

Research output: Contribution to journalReview article

Buckley, Peter F ; Charles Schulz, S. / Clozapine and risperidone : Refining and extending their use. In: Harvard Review of Psychiatry. 1996 ; Vol. 4, No. 4. pp. 184-199.
@article{e94a670268054b75b7a9b87ff8c7c859,
title = "Clozapine and risperidone: Refining and extending their use",
abstract = "The recent advent of atypical antipsychotic medications has provided new clinical options and set higher expectations for the treatment of schizophrenia and other psychoses. Two such drugs, clozapine and risperidone, are currently employed in the United States. Researchers continue to fine-tune treatment with these agents and to seek possible new uses for them. For clozapine, refinements in use (optimal duration of trial, optimal dose, use of drug plasma level to optimize efficacy) are described, along with side effects and the specificity (or lack thereof) of the drug's action upon primary negative symptoms. Also discussed is use of clozapine in new subgroups of patients for example, those with first-episode schizophrenia, polydipsia syndrome, or a dual diagnosis. For risperidone, use in patients with first-episode schizophrenia, affective disorders, autism, and other disorders is described. Cost-benefit considerations are presented for both drugs. The psychosocial needs of patients taking these medications and the potential for synergy between novel antipsychotics and modern psychosocial therapies are also discussed.",
author = "Buckley, {Peter F} and {Charles Schulz}, S.",
year = "1996",
month = "1",
day = "1",
doi = "10.3109/10673229609030543",
language = "English (US)",
volume = "4",
pages = "184--199",
journal = "Harvard Review of Psychiatry",
issn = "1067-3229",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Clozapine and risperidone

T2 - Refining and extending their use

AU - Buckley, Peter F

AU - Charles Schulz, S.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The recent advent of atypical antipsychotic medications has provided new clinical options and set higher expectations for the treatment of schizophrenia and other psychoses. Two such drugs, clozapine and risperidone, are currently employed in the United States. Researchers continue to fine-tune treatment with these agents and to seek possible new uses for them. For clozapine, refinements in use (optimal duration of trial, optimal dose, use of drug plasma level to optimize efficacy) are described, along with side effects and the specificity (or lack thereof) of the drug's action upon primary negative symptoms. Also discussed is use of clozapine in new subgroups of patients for example, those with first-episode schizophrenia, polydipsia syndrome, or a dual diagnosis. For risperidone, use in patients with first-episode schizophrenia, affective disorders, autism, and other disorders is described. Cost-benefit considerations are presented for both drugs. The psychosocial needs of patients taking these medications and the potential for synergy between novel antipsychotics and modern psychosocial therapies are also discussed.

AB - The recent advent of atypical antipsychotic medications has provided new clinical options and set higher expectations for the treatment of schizophrenia and other psychoses. Two such drugs, clozapine and risperidone, are currently employed in the United States. Researchers continue to fine-tune treatment with these agents and to seek possible new uses for them. For clozapine, refinements in use (optimal duration of trial, optimal dose, use of drug plasma level to optimize efficacy) are described, along with side effects and the specificity (or lack thereof) of the drug's action upon primary negative symptoms. Also discussed is use of clozapine in new subgroups of patients for example, those with first-episode schizophrenia, polydipsia syndrome, or a dual diagnosis. For risperidone, use in patients with first-episode schizophrenia, affective disorders, autism, and other disorders is described. Cost-benefit considerations are presented for both drugs. The psychosocial needs of patients taking these medications and the potential for synergy between novel antipsychotics and modern psychosocial therapies are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=16144365364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16144365364&partnerID=8YFLogxK

U2 - 10.3109/10673229609030543

DO - 10.3109/10673229609030543

M3 - Review article

C2 - 9384993

AN - SCOPUS:16144365364

VL - 4

SP - 184

EP - 199

JO - Harvard Review of Psychiatry

JF - Harvard Review of Psychiatry

SN - 1067-3229

IS - 4

ER -